Continuous Glucose Monitoring Device Tested in Adults With Type 2 Diabetes
Tests a glucose monitoring device in adults with type 2 diabetes who take daily insulin.
Key facts
- Who runs it
- Tulane University
- Where
- New Orleans, United StatesSee the site
- Trial code
- Registry title
- Continuous Glucose Monitoring (CGM) in an Underserved Population
- Status
- Recruiting
- People taking part
- 50 people, planned
- Started
- 19 Mar 2026
- Expected to end
- Jul 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Continuous Glucose Monitoring (CGM)
- Record updated
- 5 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 2 diabetes who take at least one insulin injection a day. They must be uninsured or on Medicaid and use clinics in the New Orleans area.
- Age
- 18 to 75 years
- Sex
- Men and women
- Disease stage
- Type 2 diabetes with HbA1C of 7.5% (58 mmol/mol) or higher
- Earlier treatment
- At least 1 insulin injection every day. People already using CGM or an insulin pump cannot join.
- Biomarker or test result
- HbA1C of 7.5% (58 mmol/mol) or higher
Main reasons for not taking part
- Type 1 diabetes
- Already using CGM or an insulin pump
- Advanced kidney disease or eGFR below 40
- End-stage kidney disease, dialysis or a kidney transplant
- Pregnant
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Age 18-75 years
- Type 2 diabetes mellitus
- HbA1C ≥ 7.5%
- At least on 1 insulin injection therapy daily
- Patients established with primary care clinic or endocrinology clinic or diabetes clinics in the New Orleans and surrounding areas
- Patients with Medicaid or free care or uninsured
- Patients must be able to speak and understand English and be capable of providing informed consent to participate in the study
Who cannot take part
- Currently on CGM or using insulin pump
- Type 1 diabetes mellitus
- Advanced renal disease or Estimated Glomerular Filtration Rate (eGFR) <40
- The patient has been diagnosed with end-stage renal disease, is on dialysis, or has had a kidney transplant, Hemoglobinopathies, iron therapy or other condition that interferes with HbA1c measurement
- Serious co-morbidities which in the investigator's opinion, will make it challenging for patients to participate
- Pregnant
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where in United States
- University Medical CenterNew Orleans, United StatesContact: Neha Upadhyay, BDS,MPHTaking people
About the trial
What the trial wants to find out
The investigators aim is to conduct a randomized clinical trial in an underserved population who are either uninsured or on Medicaid and taking at least one injection of insulin daily. The investigators believe that this study will lead to considerable alleviation of health disparities and provide better care for an underserved population. This will be a pilot study to evaluate the feasibility of such a trial in this population before doing a larger multicenter trial.
The 2 groups in the trial
- Self-Monitoring of Blood Glucose (SMBG)Placebo, for comparison
The study participants will be randomized to the self-monitoring group (control) after a period of two-week run-in and followed for 6 months. They will be given an opportunity to wear the CGM sensor for 3 months at the conclusion of the 6-month follow-up as an optional follow-up.
Treatment: Continuous Glucose Monitoring (CGM)
- Continuous Glucose Monitoring (CGM)Existing treatment, for comparison
The study participants will be randomized to the continuous glucose monitoring group (intervention).
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Continuous Glucose Monitoring in an Underserved Population: Impact on Glucose Control, Patient Reported Outcomes, Healthcare Utilization, and Long Term Complications
- Plain-language title
- Continuous Glucose Monitoring Device Tested in Adults With Type 2 DiabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07135531, who can take part
- Record updated
- 5 May 2026